Prediction of sublingual immunotherapy efficacy in allergic rhinitis by serum metabolomics analysis

Xie, Shaobing; Jiang, Sijie; Zhang, Hua; Wang, Fengjun; Liu, Yongzhen; She, Yongchuan; Jing, Qiancheng; Gao, Kelei; Fan, Ruohao; Xie, Shuang; Xie, Zhihai; Jiang, Weihong

doi:10.1016/j.intimp.2020.107211

Cited by 28 publications

(27 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the MSAR group, 109 patients were assigned to receive 3 years of standard SLIT. SLIT was conducted as previous studies described [ 10 , 23 ]. Patients were administrated with standardized Dermatophagoides farina allergen drops purchased from Wolwo Pharma Biotechnology Company (Zhejiang, China) with the drops labeled from No.1 to No.5 containing proteins of 1, 10, 100, 333, and 1000 μ g/ml, respectively.…”

Section: Methodsmentioning

confidence: 99%

“…The medication scores (MS) were evaluated as the sum of medication consumption for controlling AR symptoms over the previous week and recorded referring to the World Allergy Organization recommendations (1: oral or intranasal antihistamines, 2: nasal glucocorticoids, and 3: oral glucocorticoids) [ 26 ]. The symptom and medication score (SMS) was defined as the sum of TNSS and MS/7 as previously described [ 10 , 27 ]. We followed the methods of Xie et al [ 24 ] to evaluate the efficacy of SLIT on the basis of clinical symptom remission and the reduction in the consumption of combined pharmacologic therapy: “effective” was regarded as obtaining at least 30% reduction of SMS from the baseline level; otherwise, the SLIT was defined as ineffective.…”

Section: Methodsmentioning

confidence: 99%

“…Therefore, it is desirable to identify and exclude nonresponder patients before administrating SLIT. Although previous publications have found several potential indicators to objectively reflect the disease severity and predict the clinical response of SLIT, including serum-specific IgE, serum metabolites, and leukotriene A4 hydrolase [10][11][12], these biomarkers were not clinically available because of poor sensitivity and specificity. Thus, exploring biomarkers with high accuracy and reliability for monitoring disease severity and predicting the clinical efficacy of SLIT is extremely important.…”

Section: Introductionmentioning

confidence: 99%

“…The symptom and medication score (SMS) was defined as the sum of TNSS and MS/7 as previously described [10,27]. We followed the methods of Xie et al [24] to evaluate the efficacy of SLIT on the basis of clinical symptom remission and the reduction in the consumption of combined pharmacologic therapy: "effective" was regarded as obtaining at least 30% reduction of SMS from the baseline level; otherwise, the SLIT was defined as ineffective.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Serum Soluble ST2 Correlated with Symptom Severity and Clinical Response of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis Patients

Zhu

Cui

Chen

et al. 2021

Mediators of Inflammation

View full text Add to dashboard Cite

Background. Suppressor of tumorigenicity 2 (ST2) is a key biomarker in inflammation and cardiovascular diseases, but limited data is available on its role in allergic rhinitis (AR). Objective. The aim of this study is to explore the role of serum soluble ST2 (sST2) in evaluating disease severity and predicting the efficacy of sublingual immunotherapy (SLIT) in house dust mite- (HDM-) induced AR patients. Methods. Eighty healthy controls (HC group) and 160 HDM-induced AR patients, including 40 mild patients (MAR group) and 120 moderate-severe patients (MSAR group), were recruited in this study. Serum was collected from all participants and levels of sST2 were determined by ELISA and the relationship between sST2 levels and disease severity was assessed. In the MSAR group, 109 patients received 3 years of SLIT, and the relationship between serum levels of sST2 and efficacy of SLIT was exampled. Results. Serum sST2 levels were increased in HDM-induced AR patients compared to the HC group ( P < 0.001 ), and the concentrations were higher in the MSAR group than in the MAR group and HC group (all P < 0.05 ). Moreover, sST2 levels positively correlated with the total nasal symptom score (TNSS), visual analogue scale (VAS), and specific IgE levels ( P < 0.05 ). Seventy-eight MSAR patients accomplished SLIT, and they were divided into an effective group ( n = 40 ) and an ineffective group ( n = 38 ). The serum sST2 levels in the effective group were lower than those in the ineffective group ( P < 0.001 ). In addition, patients in the effective group levels exhibited significantly lower sST2 levels post-SLIT than pre-SLIT ( P < 0.001 ), but no statistic difference was observed in the ineffective group ( P > 0.05 ). Receiver operating characteristic (ROC) curve showed promising accuracy for predicting clinical efficacy of SLIT in AR patients ( area under the curve = 0.839 , P < 0.001 ). Conclusion. Serum sST2 is a potential biomarker for assessing disease severity and may serve as a sensitive biomarker for predicting the therapeutic response of SLIT in HDM-induced AR patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Serum Soluble ST2 Correlated with Symptom Severity and Clinical Response of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis Patients

Zhu

Cui

Chen

et al. 2021

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…Although SLIT has been demonstrated to be effective in AR, its efficacies differ between patients: some show no benefit even after prolonged treatment ( Liu et al, 2020a ; Zissler and Schmidt-Weber, 2020 ). Previous studies have explored several candidate indicators, such as serum-specific IgE ( Kim et al, 2020 ), periostin ( Hoshino et al, 2020 ), and serum metabolites ( Xie et al, 2021 ), to predict the clinical efficacy of SLIT, but the sensitivity and specificity of these potential biomarkers are not satisfactory. Therefore, identifying specific biomarkers with high accuracy and reliability for predicting the clinical responsiveness of SLIT is urgently needed to support treatment decisions.…”

Section: Introductionmentioning

confidence: 99%

Circulating MIF Associated With Disease Severity and Clinical Response of Sublingual Immunotherapy in House Dust Mite–Induced Allergic Rhinitis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Macrophage migration inhibitory factor (MIF) is described as a pro-inflammatory cytokine involved in many inflammatory and allergic disorders, but the role of MIF in allergic rhinitis (AR) remains poorly clarified. The aim of this study was to investigate the association between circulating MIF levels and house dust mite (HDM)-induced AR, and evaluate MIF as a potential biomarker in reflecting disease severity and predicting the clinical response of sublingual immunotherapy (SLIT) in HDM-induced AR patients.Methods: In this study, we enrolled 160 persistent HDM-induced AR patients (AR group), including 48 mild AR patients (MAR group) and 112 moderate–severe AR patients (MSAR group), and 77 healthy controls (HC group). Circulating levels of MIF were measured by ELISA, and the relationship between MIF concentrations and disease severity was assessed. In the MSAR group, 106 patients were assigned to receive SLIT for 3 years. At the end of the study, patients were categorized into good response group and poor response group, and associations between clinical variables or biomarkers and clinical response were analyzed by the multivariate regression analysis.Results: The concentrations of serum MIF were significantly higher in AR patients than in HCs, especially in those with MSAR. Moreover, circulating MIF levels were positively correlated with TNSS, VAS, serum HDM–specific IgE, total IgE, blood eosinophil count, and blood eosinophil percentage (all p < 0.05). Eighty MSAR patients finally completed SLIT, 45 patients obtained good response, and 35 patients resulted in poor response. The serum levels of MIF were significantly lower in the good-response group than in the poor-response group (p < 0.001). The receiver operating characteristic analysis for MIF showed good accuracy for predicting clinical response of SLIT (area under the curve = 0.877, p < 0.001). The multivariate regression analysis demonstrated that serum MIF was an independent factor for SLIT responsiveness.Conclusion: Serum MIF appeared to be an important biological indicator in reflecting disease severity and an independent predictor for clinical responsiveness of SLIT in HDM-induced AR patients.

show abstract

Long‐Term Efficacy and Safety of Subcutaneous Immunotherapy in Monosensitized and Polysensitized Children With Allergic Rhinitis

Yuan,

Xie,

Zhang

et al. 2023

Otolaryngol.--head neck surg.

Self Cite

View full text Add to dashboard Cite

ObjectiveTo evaluate the efficacy and safety of dust mite subcutaneous immunotherapy (SCIT) in monosensitized and polysensitized children with allergic rhinitis (AR).Study DesignProspective cohort study.SettingTertiary referral center.MethodsOne hundred thirty children were enrolled and categorized into 2 groups: monosensitized to only dust mites and polysensitized to at least 1 additional allergen beyond dust mites. All patients received SCIT targeting dust mites for 3 years, followed by a 5‐year monitoring period. The Total Nasal Symptom Score (TNSS), Symptom and Medication Score (SMS), Visual Analogue Scale (VAS), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) were assessed before SCIT (T0); at 1 (T1) and 2 (T2) years of SCIT; immediately after SCIT (T3); and 2 years post‐SCIT (T5). Safety was assessed based on adverse events (AEs).ResultsFifty‐one monosensitized and 50 polysensitized children completed the study. At T3, 47 monosensitized and 46 polysensitized children were effectively treated, with no significant between‐group difference in efficacy (P > .05). The TNSS, SMS, VAS scores, and RQLQ score were significantly lower at T1, T2, T3, and T5 than at T0 in both groups (P < .05). The differences in the TNSS, SMS, VAS score, and RQLQ score between the 2 groups were nonsignificant at T0, T1, T2, and T3 (P > .05), but significant at T5 (P < .05). No serious AEs were reported.ConclusionMonosensitized and polysensitized children exhibited similar beneficial efficacy and safety after 3 years of dust mite SCIT. Monosensitized children derived more benefits 2 years after discontinuation.

show abstract

Prediction of sublingual immunotherapy efficacy in allergic rhinitis by serum metabolomics analysis

Cited by 28 publications

References 51 publications

Serum Soluble ST2 Correlated with Symptom Severity and Clinical Response of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis Patients

Serum Soluble ST2 Correlated with Symptom Severity and Clinical Response of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis Patients

Circulating MIF Associated With Disease Severity and Clinical Response of Sublingual Immunotherapy in House Dust Mite–Induced Allergic Rhinitis

Long‐Term Efficacy and Safety of Subcutaneous Immunotherapy in Monosensitized and Polysensitized Children With Allergic Rhinitis

Contact Info

Product

Resources

About